Psychoactive drugs

PeakBirch Logic Announces the Acquisition of Stul Ltd

Retrieved on: 
Thursday, July 29, 2021
Psychoactive drugs, Cannabis smoking, Entheogens, Euphoriants, Medicinal plants, Cannabis, Effects of cannabis, Head shop, Manny Stul

Acquisition Accelerates Goal to Expand Cannabis Sales in the U.K. Market

Key Points: 
  • Acquisition Accelerates Goal to Expand Cannabis Sales in the U.K. Market
    PeakBirch announces the acquisition of Stul Ltd. and its brand Hot Box Herb, a leading Headshop in Chelmsford, Essex.
  • VANCOUVER, BC, July 29, 2021 /PRNewswire/ -PeakBirch Logic Inc. (CSE: PKB) (FSE: KYH2) (OTCQB: KTNNF) ("PeakBirch" or the "Company") is pleased to announce the closing of the acquisition (the "Acquisition") of Stul Ltd. ("Stul" or the "Seller"), located in London, United Kingdom.
  • As part of the Acquisition, PeakBirch acquired Hot Box Herb, a leading brick and mortar cannabis accessory shop (a headshop) and e-commerce website.
  • With the acquisition of Stul, PeakBirch will receive 350K GBP in working capital which includes approximately 150K GBP in inventory, including shisha, tobacco and pipes, cannabis accessories, high-end designer bongs, and CBD.

Tryp Therapeutics Announces Q3 2021 Financial Results

Retrieved on: 
Thursday, July 29, 2021
Health sciences, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Pharmaceutical industry, Psychoactive drugs, Pharmaceutical sciences

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.

Key Points: 
  • Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.
  • Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience.
  • In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.
  • These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully.

Avicanna Completes First Commercial Export of Aureus™ Branded THC Extracts to Austria and Welcomes Colombian Government’s Progressive New Regulation on Cannabis

Retrieved on: 
Wednesday, July 28, 2021
Entheogens, Euphoriants, Medicinal plants, Psychoactive drugs, Branches of biology, Drugs, Appetite stimulants, Herbalism, Cannabis, Tetrahydrocannabinol, Medical cannabis, Hemp

TORONTO, July 28, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH”), it has completed its first commercial export of high concentration THC full spectrum psychoactive cannabis extracts to Austria. Additionally, the company welcomes the new Colombian regulation aimed at progressing the cannabis industry and its commercialization processes which positively impacts several of Avicanna’s business units and infrastructure in Colombia.

Key Points: 
  • This initial export to Austria marks Avicannas first commercial export of psychoactive THC Cannabis Extracts into the emerging European medicinal cannabis market.
  • (SMGH), it has completed its first commercial export of high concentration THC full spectrum psychoactive cannabis extracts to Austria.
  • Additionally, the company welcomes the new Colombian regulation aimed at progressing the cannabis industry and its commercialization processes which positively impacts several of Avicannas business units and infrastructure in Colombia.
  • This shipment marks the 9th country to which SMGH has exported the Aureus branded products, which include a range of CBD, THC and CBG extracts and feminised seeds.

180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue

Retrieved on: 
Wednesday, July 28, 2021
Medicinal plants, Psychoactive drugs, Health sciences, Entheogens, Euphoriants, Herbalism, Cannabis smoking, Medicine, Cannabis, Raphael Mechoulam, Medical cannabis, Effects of cannabis

MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain.

Key Points: 
  • MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain.
  • As part of a continuing collaboration since 1998 with the pioneer of cannabis chemistry, Raphi Mechoulam (Hebrew University, Jerusalem), Sir Marc Feldmanns (the Companys Co-Executive Chairman and Co-Founder) laboratory, and 180 Life Sciences scientists, identified the non-psychoactive CBD analogue as a lead molecule in the Companys SCA platform.
  • Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated, We believe that our lead compound HUM-217, a CBD derivative generated by cannabis chemistry pioneer Prof Raphael Mechoulam, meets all the criteria desirable to advance to clinical development.
  • 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation.

Pear Therapeutics Announces Publication of Healthcare Resource Utilization Data Analysis Showing Real-World Cost Impact of reSET-O® in Treating Opioid Use Disorder

Retrieved on: 
Wednesday, July 28, 2021
Technology, Mental health, Mobile, Wireless, Hospitals, Software, Internet, Health, Pharmaceutical, General Health, Opioids, Drugs, Psychoactive drugs, Morphinans, Substance dependence, Tertiary alcohols, Ethers, Phenols, Opioid use disorder, Buprenorphine, Opioid epidemic in the United States, Co-prescribing naloxone with opioids

Pear Therapeutics, Inc. , today announced publication of a new analysis demonstrating the real-world cost impact of reSET-O, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD).

Key Points: 
  • Pear Therapeutics, Inc. , today announced publication of a new analysis demonstrating the real-world cost impact of reSET-O, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD).
  • In recent years, OUD has been responsible for approximately two out of every three deaths related to substance use disorder (SUD)14-16.
  • Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population.
  • Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder.

Colorado State University Launches CBD Veterinary Survey

Retrieved on: 
Wednesday, July 28, 2021
Psychoactive drugs, Entheogens, Cannabis smoking, Euphoriants, Medicinal plants, Health sciences, Effects of cannabis, Cannabis, Veterinarian, Colorado State University, Veterinary medicine

DENVER, July 28, 2021 /PRNewswire/ -- Colorado State University professors and principal investigators, Dr. Stephanie McGrath and Dr. Felix Duerr, are leading a survey of pet owners to help researchers and veterinarians understand consumer attitudes toward the use of CBD/cannabis products in veterinary patients.

Key Points: 
  • DENVER, July 28, 2021 /PRNewswire/ --Colorado State University professors and principal investigators, Dr. Stephanie McGrath and Dr. Felix Duerr, are leading a survey of pet owners to help researchers and veterinarians understand consumer attitudes toward the use of CBD/cannabis products in veterinary patients.
  • Nationally recognized for their extensive CBD research, McGrath and Duerr's latest CBD study will gather information on veterinary recommendations of CBD/cannabis products for their clients' pets.
  • The CBD veterinary research study is made possible through funding from Colorado based, RYTE CBD .
  • "CSU's College of Veterinary Medicine and Biomedical Sciences is a national leader in animal health research and treatment, and we are proud to support Dr. McGrath's and Dr. Duerr's research on possible veterinary CBD applications," said RYTE CBD CEO Eric White.

Global Cannabidiol Market Size Expected to Reach $2.8 Billion by 2028 with a CAGR of 21%

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Organ systems, Psychoactive drugs, Cannabinoids, Resorcinols, Appetite stimulants, Entheogens, Euphoriants, Cannabidiol, Cannabis, Hemp

A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.

Key Points: 
  • A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.
  • Grand View added: "Furthermore, the use of hemp-derived CBD is increasing rapidly owing to its anti-inflammatory, anti-aging, and antioxidant properties.
  • This rapidly progressing transformation of cannabidiol from herbal preparations to prescription drugs is anticipated to boost the growth of the market.
  • Furthermore, growing awareness about the medical benefits of cannabidiol, including its healing properties, is anticipated to drive the product demand in the pharmaceutical industry."

NEOGEN Launches Reveal® Q+ for Δ9-THC in Hemp

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Psychoactive drugs, Euphoriants, Appetite stimulants, Entheogens, Organ systems, Cannabis, Cannabinoids, Tetrahydrocannabinol, Hemp, Cannabidiol

NEOGEN's new Reveal Q+ for 9-THC can precisely detect and report THC levels between 0.1% and 1.6%, providing fast, reliable, and on-demand crop monitoring.

Key Points: 
  • NEOGEN's new Reveal Q+ for 9-THC can precisely detect and report THC levels between 0.1% and 1.6%, providing fast, reliable, and on-demand crop monitoring.
  • "The addition of the ability to test for 9-THC to our Reveal Q+ portfolio puts the power in the hands of hemp farmers," says John Adent, NEOGEN's President and CEO.
  • Hemp has various uses, including rope and textiles, feed and grain, and cannabidiol (CDB), commonly used in body care products and supplements.
  • NEOGEN Corporation develops and markets comprehensive solutions dedicated to food and animal safety.

Global Cannabidiol Market Size Expected to Reach $2.8 Billion by 2028 with a CAGR of 21%

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Organ systems, Psychoactive drugs, Cannabinoids, Resorcinols, Appetite stimulants, Entheogens, Euphoriants, Cannabidiol, Cannabis, Hemp

PALM BEACH, Fla., July 28, 2021 /PRNewswire/ -- Cannabidiol derived from hemp is anticipated to witness rapid growth owing to increasing demand from the pharmaceutical sector and rising awareness among consumers regarding health. Increasing consumer disposable income along with the legalization of medicinal cannabis is anticipated to have a positive impact on the demand for cannabidiol in the pharmaceutical sector. Oils, tinctures, concentrate, capsules, topical solutions such as slaves, lip balms, lotions, and edibles such as baked goods, coffee, chocolates, gums, and candies are some of the CBD products which are in high demand. Due to its healing properties, the demand for cannabidiol (CBD) for health and wellness purposes is high, which is the major factor driving the market growth. In addition, the rising acceptance and use of products due to government approvals is a major factor expected to boost production for CBD-infused products.  A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.  Active Companies in the merchant industry include Grove, Inc. (NASDAQ: GRVI), Tilray, Inc. (NASDAQ: TLRY) (TSX: TLRY), Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), Pressure BioSciences, Inc. (OTCQB: PBIO), cbdMD, Inc. (NYSE: YCBD).

Key Points: 
  • A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.
  • Grand View added: "Furthermore, the use of hemp-derived CBD is increasing rapidly owing to its anti-inflammatory, anti-aging, and antioxidant properties.
  • This rapidly progressing transformation of cannabidiol from herbal preparations to prescription drugs is anticipated to boost the growth of the market.
  • Furthermore, growing awareness about the medical benefits of cannabidiol, including its healing properties, is anticipated to drive the product demand in the pharmaceutical industry."

Switching Isn't Quitting - Allen Carr's Easyway Supports World Health Organization's Call to Regulate E-Cigarettes

Retrieved on: 
Wednesday, July 28, 2021
Psychoactive drugs, Tobacco, Electronic cigarettes, Smoking cessation, Nicotinic agonists, Health effects of tobacco, Substance-related disorders, Electronic cigarette, Allen Carr, Cigarette, Nicotine, Smoking

The report finds that children who use these products are up to twice as likely to use tobacco products in the future.

Key Points: 
  • The report finds that children who use these products are up to twice as likely to use tobacco products in the future.
  • As such, both WHO and Allen Carr's Easyway recommend tighter regulations to stop non-smokers from starting to use them, to prevent renormalization of smoking in the community and to protect future generations.
  • The WHO report on The Global Tobacco Epidemic, presents new data on electronic nicotine delivery systems, such as 'e-cigarettes'.
  • In fact, WHO will soon publish a paper calling on countries to invest in tobacco cessation with the recommended interventions."